



**Date: 25<sup>th</sup> May, 2026**

**To,**  
**BSE Ltd.,**  
**Listing Department,**  
Phiroze Jeejeebhoy Towers,  
Dalal Street - Fort,  
Mumbai – 400 001

**Scrip Code: 539730**

**Sub.: Press Release issued by Fredun Pharmaceuticals Limited**

Dear Sir/ Madam,

Please find enclosed press release titled **“Fredun Pharmaceuticals Delivers Robust FY26 Performance; Revenue Jumps 40%, EBITDA Surges 72% and Profit Rises ~60% YoY”** issued by Fredun Pharmaceuticals Limited.

Kindly take the same on your records.

Thanking you,

Yours truly,

**For Fredun Pharmaceuticals Limited**

**Fredun Nariman Medhora**  
**Managing Director**  
**DIN: 01745348**





## Fredun Pharmaceuticals Delivers Robust FY26 Performance; Revenue Jumps 40%, EBITDA Surges 72% and Profit Rises ~60% YoY

**Mumbai – May 25, 2026:** Fredun Pharmaceuticals Limited (BSE – FREDUN | 539730), one of the leading pharmaceutical formulation manufacturing companies in India, diversified across generics, cosmeceuticals, nutraceuticals, mobility, and animal healthcare products, has reported its audited financial results for Q4 FY26 and FY26.

### Key Financial Highlights

Particulars (₹ Cr)	Standalone					
	Q4 FY26	Q4 FY25	YoY	FY26	FY25	YoY
Total Income	213.05	167.41	↑ 27.27%	639.12	456.27	↑ 40.08%
EBITDA	29.13	17.44	↑ 67.05%	94.79	55.10	↑ 72.05%
EBITDA Margin (%)	13.67%	10.42%	↑326 Bps	14.83%	12.08%	↑276 Bps
Net Profit	11.07	7.07	↑ 56.47%	33.21	20.81	↑ 59.59%
Net Profit Margin (%)	5.19%	4.22%	↑ 97 Bps	5.20%	4.56%	↑ 64 Bps

### Performance Highlights & Key Announcement:

- FY26 revenue scales to ₹639 Cr, up 40% YoY, reflecting strong demand traction
- EBITDA jumps 72% YoY to ~₹95 Cr, with margins expanding to 14.8%
- PAT surges ~60% YoY to ₹33 Cr, significantly outpacing revenue growth
- Margins expand across the board, led by operating leverage and cost discipline
- Q4 exits on a strong note, with EBITDA up 67% and PAT up 56% YoY
- Profitability accelerating faster than revenue, indicating improving business quality
- Improved financial ratios and positive cash flow generation, strengthening overall financial health
- **Recommended Dividend of ₹0.70 per share** recommended by the Board
- **Recommended issuance of bonus shares in the ratio of 2:1, i.e. 2 fully paid-up equity shares of ₹10 each for every 1 existing share of ₹10 each**, to eligible shareholders/warrant holders as on the record date, subject to shareholder approval.

**Commenting on the financial performance Mr. Fredun Medhora, Managing Director, said, “FY26 reflects the steady progress we have made in building a diversified and resilient business. Our growth is coming across segments, with continued strength in generics complemented by increasing traction in nutraceuticals, cosmeceuticals, and pet care. This balanced mix is helping us scale more sustainably and reduce dependence on any single segment. The improvement is clearly visible in our performance, with revenue reaching ₹639 crore and margins strengthening during the year.**

*At the same time, we have started investing in the next phase of growth. The launch of our premium hormone therapy range and the DAULCÉL platform marks our entry into more specialized, wellness and preventive healthcare segments. These are early steps, but they open up new avenues beyond our traditional business. Alongside this, the expansion of our Palghar facility and the upgrade in our credit rating to IVR BBB+ give us the capacity and financial strength to support future growth.*

*Going forward, our focus will be on continuing to build across segments while gradually increasing the share of differentiated and higher value products. With multiple growth drivers now in place and a*

*stronger base established, we are confident of sustaining this momentum and delivering consistent growth in the years ahead.”*

### Recent Key Business Highlights

<b>Hormone Range Products</b>	<ul style="list-style-type: none"> <li>Announced launch of premium hormone therapeutics range focused on longevity, hormone health, and performance care</li> <li>Doctor-led, evidence-backed model with digital-first patient engagement</li> </ul>
<b>DAULCÉL Platform</b>	<ul style="list-style-type: none"> <li>Announced launch of ‘DAULCÉL’ – premium NAD+ based wellness &amp; longevity platform</li> <li>Expands into preventive healthcare, healthy aging, and lifestyle wellness segments</li> </ul>
<b>Fifth Facility Expansion at Palghar</b>	<ul style="list-style-type: none"> <li><b>Adds 40,000 sq. ft. manufacturing capacity.</b></li> <li>Expected to be operational by October 2026; Supports veterinary, nutraceutical and pharmaceutical formulations</li> <li>Additional 50,000 sq. ft. planned Expansion</li> </ul>
<b>Credit Rating Upgrade</b>	<ul style="list-style-type: none"> <li>Infomerics upgrades credit rating to <b>IVR BBB+ (Stable)</b> from IVR BBB (Stable)</li> <li>Rating covers bank facilities of <b>~₹156.17 crore</b></li> <li>Strengthened banking confidence and institutional credibility</li> </ul>

### About Fredun Pharmaceuticals Limited

Fredun Pharmaceuticals Limited, healthcare and pharmaceuticals company offer a range of products, including antihypertensives, antidiabetic, antiretroviral drugs (ARVs) and narcotics. It is also engaged in the manufacturing of dietary/herbal supplements, nutraceuticals, cosmeceuticals, and other healthcare products along with animal healthcare products. With such a diverse range of products, the Company’s objective is to be a holistic healthcare provider. The Company primarily exports its products to Africa, Southeast Asia, Commonwealth of Independent States (CIS) countries and Latin America.

In the FY26, Fredun reported total revenues of ₹639.12 Cr, with an EBITDA of ₹94.79 Cr and a PAT of ₹33.21 Cr.

### Disclaimer

Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. The Company will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.

For Further Information Please Contact Corporate Communication Advisor



**Kirin Advisors Private Limited**

Sunil Mudgal - Director

[sunil@kirinadvisors.com](mailto:sunil@kirinadvisors.com)

+91 98692 75849

[www.kirinadvisors.com](http://www.kirinadvisors.com)